Adds details throughout
Dec 11 (Reuters) - Candel Therapeutics CADL.O said on Wednesday its experimental immunotherapy for prostate cancer met the main goal of a late-stage trial, helping the company's shares more than double in value in premarket trading.
The immunotherapy, CAN-2409, in combination with radiation therapy significantly improved disease-free survival in patients, compared to radiation alone, the company said.
Candel said it plans to discuss with the Food and Drug Administration regarding the therapy in intermediate-to-high-risk localized prostate cancer.
Over 100,000 men are diagnosed with prostate cancer every year in the U.S., the company said.
The company's shares were up 176.8% at $12.76 in trading before the bell.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。